10-Q: Aprea Therapeutics Faces Going Concern Doubt Amid Cash Burn

Aprea Therapeutics reported significant losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, despite ongoing clinical development.

Summary

• Aprea Therapeutics, a clinical-stage biopharmaceutical company, reported a cash and cash equivalents balance of $13.7 million as of September 30, 2025, down from $22.8 million at December 31, 2024.
• The company incurred a net loss of $10.1 million for the nine months ended September 30, 2025, slightly higher than the $10.06 million loss for the same period in 2024.
• An accumulated deficit of $331.2 million was reported as of September 30, 2025, up from $321.0 million at December 31, 2024.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months without additional funding.
• Grant revenue significantly decreased to $282,422 for the nine months ended September 30, 2025, from $1.3 million in the prior year period.
• Research and development expenses decreased by $1.0 million to $6.0 million for the nine months ended September 30, 2025, primarily due to reduced spending on the ATRN-119 clinical trial and personnel costs.
• General and administrative expenses decreased by $0.5 million to $4.8 million for the nine months ended September 30, 2025, mainly due to lower professional fees and insurance premiums.
• The company's lead WEE1 inhibitor, APR-1051, is in a Phase 1 dose escalation study (ACESOT-1051), with open-label safety/efficacy data anticipated in Q1 2026 and dose-escalation completion in H1 2026.
• Enrollment in the monotherapy arms of the ATRN-119 Phase 1/2a study (ABOYA-119) was voluntarily paused in October 2025 to explore combination approaches, following the determination of a recommended Phase 2 dose of 1,100 mg once daily.
• The company raised approximately $0.8 million in net proceeds from at-the-market (ATM) stock sales during the nine months ended September 30, 2025, significantly less than the $14.7 million from financing activities in the prior year period.
• A total of 25,033 shares of Series A Preferred Stock were converted into 12,516 shares of common stock in April 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with a 'going concern' warning and significantly reduced cash. While there's strategic clinical progress, the immediate financial outlook is highly negative, indicating extreme risk.

Positives

• APR-1051, a WEE1 inhibitor, is progressing in its Phase 1 dose escalation study (ACESOT-1051) with open-label safety/efficacy data expected in Q1 2026 and dose-escalation completion in H1 2026.
• The recommended Phase 2 dose (RP2D) of 1,100 mg once daily for ATRN-119 in monotherapy was determined on October 15, 2025, providing clarity for future development.
• The strategic pause in ATRN-119 monotherapy enrollment aims to explore combination approaches, potentially expanding its therapeutic potential and leveraging preclinical data suggesting synergistic anti-tumor effects.
• Discussions are underway with leading academic centers to explore combining ATRN-119 with radiation in HPV+ head and neck cancer, and investigator-led studies with I/O agents and antibody-drug conjugates are also being explored.
• Research on the combination of ATRN-119 and APR-1051 is supported by a SBIR grant from the National Cancer Institute, indicating external validation and funding for pipeline synergy.

Negatives

• The company's cash and cash equivalents decreased significantly to $13.7 million as of September 30, 2025, from $22.8 million at December 31, 2024.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months.
• The accumulated deficit increased to $331.2 million as of September 30, 2025, reflecting continued operating losses.
• Grant revenue declined sharply to $282,422 for the nine months ended September 30, 2025, from $1.3 million in the prior year, reducing a source of non-dilutive funding.
• Net cash provided by financing activities for the nine months ended September 30, 2025, was only $0.8 million, a substantial decrease from $14.7 million in the prior year, indicating reduced access to capital.
• The voluntary pause in further patient enrollment for ATRN-119 monotherapy arms, while strategic, introduces delays and uncertainty regarding its standalone development path.

Risks

• The company has incurred significant losses since inception and expects to incur losses for the foreseeable future, potentially never achieving or maintaining profitability.
• Substantial doubt exists about the company's ability to continue as a going concern, requiring additional funding that may not be available on acceptable terms or at all.
• The company is substantially dependent on the success of APR-1051 and ATRN-119, both in early clinical development, and their clinical trials may not be successful.
• Results of preclinical studies and early-stage clinical trials may not be predictive of future results in later studies or trials, and initial success may not be indicative of final outcomes.
• Difficulty in enrolling patients in clinical trials could delay or prevent necessary marketing approvals.
• Identification of serious adverse or unacceptable side effects or limited efficacy during development could lead to abandonment or limitation of product candidate development.
• Reliance on third parties for clinical trials and manufacturing poses risks of unsatisfactory performance, non-compliance with regulations, or failure to meet deadlines.
• Inability to obtain and maintain intellectual property protection for product candidates or technology could allow competitors to commercialize similar products.
• The company has never obtained marketing approval for a product candidate, and the approval process is expensive, time-consuming, and uncertain.
• Relationships with healthcare providers, physicians, and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws, potentially exposing the company to penalties.
• Employees and consultants may engage in misconduct or improper activities, leading to significant liability and reputational harm.
• IT system failures, cybersecurity attacks, data breaches, or vulnerabilities could compromise sensitive information and expose the company to liability.
• The price of the company's common stock has been and may continue to be volatile, influenced by clinical trial results, regulatory actions, competition, and financing efforts.
• Failure to meet Nasdaq continued listing requirements could lead to delisting, negatively affecting stock price and ability to raise capital.
• Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect product candidates.
• Product liability lawsuits could result in substantial liabilities, potentially exceeding insurance coverage.
• Governments outside the United States may impose strict price controls, adversely affecting revenues from product sales.
• The p53 reactivation approach (eprenetapopt) is a novel and unproven therapeutic approach, with prior clinical setbacks and a shift in primary focus away from this program.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future. Existing cash and cash equivalents are projected to fund operations only into the fourth quarter of 2026. The company is actively seeking additional funding and may need to significantly reduce expenditures or curtail new development activity if funds are not secured. APR-1051 is expected to provide open-label safety/efficacy data in Q1 2026 and complete dose-escalation in H1 2026. ATRN-119 development is shifting towards combination approaches, with discussions ongoing for investigator-led studies.

Management Comments

• "The Company believes that the September 30, 2025 cash balance of approximately $13.7 million will not be sufficient to fund the Companys operating expenses and capital expenditure requirements through at least twelve months from the date of issuance of these condensed consolidated financial statements. Therefore, the Company has concluded that substantial doubt exists about its ability to continue as a going concern."
• "The Company is in the process of seeking additional funding. In the event that additional funds are not available, management would expect to significantly reduce expenditures to conserve cash, which would involve scaling back or curtailing new development activity."
• "Given the encouraging tolerability profile to date, we are in a position to accelerate dose escalation and explore higher doses, potentially improving APR-1051 therapeutic impact."
• "Building on the completion of dose escalation and supported by new preclinical data suggesting potential synergistic anti-tumor effects, we are considering further ATRN-119 development in combination approaches that could expand its therapeutic potential."
• "We believe ATRN-119's mechanism of action, favorable safety profile, and pharmacologic characteristics make it an ideal candidate for combination with other anti-cancer therapies, including radiation therapy, antibody-drug conjugates and immune checkpoint inhibitors."
• "As part of this strategic focus, we voluntarily paused further enrollment in both once daily and twice daily monotherapy dosing arms of ABOYA-119."
• "We do not currently have any ongoing preclinical studies or clinical trials involving our reactivators of mutant p53 and our primary focus is on the discovery and development of molecules targeting DDR pathways in oncology through synthetic lethality."

Industry Context

Aprea Therapeutics operates in the highly competitive biopharmaceutical and cancer drug sectors, characterized by rapid technological advancements and a strong emphasis on proprietary new drugs. The company is pursuing synthetic lethality, an emerging strategy in oncology, with its WEE1 and ATR inhibitors. While PARP inhibitors (e.g., Lynparza, Rubraca, Zejula, Talzenna, Pamiparib) have achieved market approval, no other synthetic lethality small molecule inhibitors have been FDA-approved to date. Aprea faces competition from major pharmaceutical and biotechnology companies with significantly greater resources and expertise, including those developing similar WEE1 and ATR inhibitors.

Comparison to Industry Standards

• The company's focus on synthetic lethality through DDR pathway targeting (WEE1 and ATR inhibitors) aligns with an emerging and promising area in oncology, similar to the success seen with PARP inhibitors like AstraZeneca's Lynparza, Clovis Oncology's Rubraca, GSK's Zejula, and Pfizer's Talzenna.
• Unlike established PARP inhibitors, Aprea's WEE1 and ATR inhibitors are in early clinical stages, with no FDA-approved synthetic lethality small molecule inhibitors (other than PARP inhibitors) currently on the market, indicating a high-risk, high-reward profile.
• Competitors in the WEE1 inhibitor space include Debiopharm, IMPACT Therapeutics, Schrodinger, and Zentalis Pharmaceuticals, suggesting a crowded field for APR-1051.
• Competitors in the ATR inhibitor space include Artios Pharma Ltd., AstraZeneca Plc, Bayer AG, IMPACT Therapeutics, Inc., and Repare Therapeutics, Inc., indicating significant competition for ATRN-119.
• The voluntary pause in ATRN-119 monotherapy enrollment to pursue combination therapies is a strategic pivot, common in drug development to optimize efficacy and market potential, but it also introduces delays compared to a direct monotherapy path.

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Stakeholder Impact

• **Shareholders**: Face significant risk of dilution from potential future equity financings and substantial risk of investment loss due to the 'going concern' doubt and continued operating losses. The stock price is likely to remain volatile.
• **Employees**: May face uncertainty regarding job security if the company is unable to secure additional funding and is forced to significantly reduce expenditures or curtail development activities.
• **Customers (future)**: Potential patients and healthcare providers may experience delays or cessation of development for promising product candidates if funding issues persist.
• **Creditors/Suppliers**: May face increased risk of delayed or non-payment if the company's financial condition deteriorates further.
• **Regulatory Authorities**: The company's ability to meet regulatory requirements and advance clinical trials could be impacted by financial constraints.

Next Steps

• Seek additional funding to address the going concern doubt and fund operating expenses and capital expenditure requirements.
• Continue the Phase 1 dose escalation study (ACESOT-1051) for APR-1051, with open-label safety/efficacy data expected in Q1 2026 and dose-escalation completion in H1 2026.
• Explore and initiate combination approaches for ATRN-119, including discussions with academic centers for combination with radiation in HPV+ head and neck cancer.
• Explore additional investigator-led studies for ATRN-119 in combination with I/O agents and antibody-drug conjugates.
• Continue early preclinical research for an undisclosed DDR target in the lead optimization stage.
• Evaluate the impact of new accounting pronouncements (ASU 2024-03) for future financial disclosures.

Key Dates

Recommendation

The filing explicitly states 'substantial doubt exists about its ability to continue as a going concern' and that existing cash will only fund operations into Q4 2026. This severe liquidity crisis, coupled with ongoing significant losses and a drastic reduction in recent financing proceeds, presents an extremely high risk profile. While there is some strategic clinical progress, the fundamental financial viability is in question, making the stock highly speculative and unsuitable for most investors. A seasoned investor would recognize the imminent need for significant capital and the high probability of substantial dilution or even cessation of operations if funding is not secured on favorable terms.

Keywords

Aprea Therapeutics, APRE, Biopharmaceutical, Oncology, Synthetic Lethality, WEE1 inhibitor, APR-1051, ATR inhibitor, ATRN-119, Clinical Trials, Phase 1, Cancer Therapeutics, DNA Damage Response, Going Concern, Liquidity, SEC Filing, 10-Q, Biotech, Drug Development, Financial Health